Newsletter | February 6, 2020

02.06.20 -- How To Improve Vaccine Production And Overcome Process Challenges

Enabling Vaccine Production: Solving Challenges Together

The constant threat posed by pathogens drives the demand for effective, safe, and affordable vaccines. However, the complexity and variety of vaccine types and manufacturing methods has prevented the establishment of robust processing templates. This e-book contains a series of case studies focusing on the more efficient and cost-effective manufacture of vaccines.

Developing An Accelerated And More Cost-Effective Single-Use Adenoviral Vector Vaccine Manufacturing Process Through Public-Private Collaboration

While remarkable progress has been made in eradicating devastating diseases, such as smallpox and polio, the global population remains at risk due to difficulties accessing vaccines, shortages in supply, slow responses to outbreaks and pandemics, and the presence of emerging pathogens. This article describes developing an optimized, single-use GMP process for manufacturing adenoviral vector-based vaccines.

Vaccine Manufacturing: Collaboration Helps To Overcome Vaccine Process Challenges

Learn how collaborative technology development efforts carried out by the DiViNe consortium advance the use of an innovative affinity chromatography platform during vaccine manufacturing. This article also discusses how long-term partnerships with strategic technology experts can help overcome inherent issues that arise as promising vaccine candidates move through scale-up, from proof-of-concept through commercial-scale manufacturing.

Neglected Tropical Diseases: Improving The Manufacturing Paradigm For A Novel Recombinant Protein Vaccine

Schistosomiasis is a chronic parasitic infection that ranks second only to malaria on the list of the world’s most devastating infectious diseases according to the World Health Organization. Learn how researchers are combining their bioprocess and engineering expertise to advance and optimize the manufacturing process for a promising new preventive recombinant protein-based vaccine against schistosomiasis.

Producing Conjugate Polysaccharide (CPS) Vaccines: When To Consider Customized Ultrafiltration Membranes

CPS (conjugate polysaccharide) vaccines are very challenging to process, requiring substantial compromises between purity and yields. This is particularly apparent during the separation of conjugated polysaccharide from free polysaccharide, which can be similar in molecular size. A combination of process parameter/system modifications and implementation of customized tangential flow filtration (TFF) membranes can be highly effective at solving these process challenges.